Collectively, these data highlight p62 as a novel independent prognostic biomarker for AJCC stage II melanomas, providing a powerful tool for refining the risk of disease progression and enabling earlier patient therapeutic intervention. The gene discussed is SQSTM1; the disease is melanoma.